Literature DB >> 25360219

Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Jacob I Tower1, Mark W Lingen2, Tanguy Y Seiwert3, Alexander Langerman1.   

Abstract

OBJECTIVES: To quantitatively and visually characterize changes in phosphorylated biomarker expression in head and neck squamous cell carcinoma specimens from excision through 90 minutes of warm ischemia.
MATERIALS AND METHODS: Tissue biospecimens were procured prospectively. Head and neck squamous cell carcinoma specimens from 5 patients were subdivided into three parts upon excision, exposed to warm ischemia of 15, 30, or 90 minutes, and routinely biobanked. Relative change in biomarker expression of p-Akt, p-ERK, and p-Stat3 was measured by immunoblot densitometry. Immunofluorescent stains were performed to visually supplement the quantitative analysis.
RESULTS: From 15 to 30 minutes of ex vivo ischemia, there was a significant decrease in p-Akt (p = 0.045) as the mean intensity fell by 44.9%. This decrease in p-Akt remained significant at the 90 minute time point (p = 0.015). From 15 to 30 minutes of ischemia, there was a trend toward a decline in p-ERK, which became significant by 90 minutes of ex vivo warm ischemia (p = 0.008). These changes were supported by qualitative differences in p-ERK fluorescence at 0 and 90 minutes warm ischemia.
CONCLUSION: Some phosphorylated biomarkers of HNSCC remain highly dynamic during the period of ex vivo warm ischemia after surgical excision but before biobanking. These findings have critical implications for studies that attempt to correlate protein phosphorylation with clinical outcome. We conclude that ex vivo warm ischemia time is a major determinant of tissue quality that may explain inconsistent results from biomarker research in head and neck squamous cell carcinoma.

Entities:  

Keywords:  Biobanking; biomarkers; head and neck squamous cell carcinoma; phosphorylated biomarkers; warm ischemia

Year:  2014        PMID: 25360219      PMCID: PMC4212929     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  32 in total

Review 1.  Signaling--2000 and beyond.

Authors:  T Hunter
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  A portrait of tissue phosphoprotein stability in the clinical tissue procurement process.

Authors:  Virginia Espina; Kirsten H Edmiston; Michael Heiby; Mariaelena Pierobon; Manuela Sciro; Barbara Merritt; Stacey Banks; Jianghong Deng; Amy J VanMeter; David H Geho; Lucia Pastore; Joel Sennesh; Emanuel F Petricoin; Lance A Liotta
Journal:  Mol Cell Proteomics       Date:  2008-07-30       Impact factor: 5.911

3.  Bring on the biomarkers.

Authors:  George Poste
Journal:  Nature       Date:  2011-01-13       Impact factor: 49.962

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Biospecimen Reporting for Improved Study Quality.

Authors:  Helen M Moore; Andrea Kelly; Scott D Jewell; Lisa M McShane; Douglas P Clark; Renata Greenspan; Pierre Hainaut; Daniel F Hayes; Paula Kim; Elizabeth Mansfield; Olga Potapova; Peter Riegman; Yaffa Rubinstein; Edward Seijo; Stella Somiari; Peter Watson; Heinz-Ulrich Weier; Claire Zhu; Jim Vaught
Journal:  Biopreserv Biobank       Date:  2011-04       Impact factor: 2.300

6.  Akt activation correlates with adverse outcome in tongue cancer.

Authors:  Erminia Massarelli; Diane D Liu; J Jack Lee; Adel K El-Naggar; Lorenzo Lo Muzio; Stefania Staibano; Sabino De Placido; Jeffrey N Myers; Vassiliki A Papadimitrakopoulou
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

7.  Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.

Authors:  Anjali K Gupta; W Gillies McKenna; Charles N Weber; Michael D Feldman; Jeffrey D Goldsmith; Rosemarie Mick; Mitchell Machtay; David I Rosenthal; Vincent J Bakanauskas; George J Cerniglia; Eric J Bernhard; Randal S Weber; Ruth J Muschel
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

8.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

Authors:  Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

Review 9.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

10.  EGFR and phosphorylated EGFR in relation to HPV and clinical outcome in tonsillar cancer.

Authors:  Mircea Romanitan; Anders Näsman; Eva Munck-Wikland; Tina Dalianis; Torbjörn Ramqvist
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.